Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan.
The Gastrointestinal Cancer Biology, International Research Center of Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.
Anticancer Res. 2021 Jun;41(6):2895-2900. doi: 10.21873/anticanres.15071.
BACKGROUND/AIM: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignant tumor. Research using an innovative research approach is needed to identify effective biomarkers or therapeutic targets for PDAC. We aimed to identify proteins related to the peritoneal dissemination of PDAC.
We performed proteomic analysis using ascites samples from patients with advanced PDAC and peritoneal dissemination and patients with liver cirrhosis (LC). Proteins specific to PDAC were identified in comparison to the findings for ascites from patients with LC as a control group.
In total, 336 proteins were identified in ascites from patients with PDAC. We identified 18 specific proteins in ascites from patients with advanced PDAC. Among these proteins, CD13, lymphatic vessel endothelial hyaluronan receptor 1, ficolin-3, and V-set and immunoglobulin domain containing 4 were the most frequently detected. In addition, these 18 proteins could be classified into four categories: extracellular matrix, immunity, metabolism, and others.
The identified proteins could be informative for developing treatment strategies for patients with PDAC and peritoneal dissemination.
背景/目的：胰腺导管腺癌（PDAC）是一种侵袭性恶性肿瘤。需要采用创新的研究方法来研究，以确定 PDAC 的有效生物标志物或治疗靶点。我们旨在鉴定与 PDAC 腹膜扩散相关的蛋白质。
我们使用来自晚期 PDAC 和腹膜扩散患者以及肝硬化（LC）患者的腹水样本进行蛋白质组学分析。与作为对照组的 LC 患者腹水的结果进行比较，鉴定 PDAC 特异性蛋白。
总共在 PDAC 患者的腹水中鉴定出 336 种蛋白质。我们在晚期 PDAC 患者的腹水中鉴定出 18 种特异性蛋白。在这些蛋白质中，CD13、淋巴管内皮透明质酸受体 1、ficolin-3 和 V -set 及免疫球蛋白结构域包含 4 是最常检测到的。此外，这些 18 种蛋白质可以分为四类：细胞外基质、免疫、代谢和其他。
鉴定出的蛋白质可能为 PDAC 和腹膜扩散患者的治疗策略提供信息。
